시장보고서
상품코드
1630679

브루가다 증후군 시장 규모, 점유율, 성장 분석 : 진단별, 약제별, 치료별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Brugada Syndrome Market Size, Share, Growth Analysis, By Diagnosis (Electrocardiogram, Electrophysiology (Ep) Test), By Drugs (Antiarrhythmic drugs, Psychotropic drugs), By Treatment, By End user, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 158 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 브루가다 증후군 시장 규모는 2023년에 14억 달러로 평가되며, 2024년 14억 8,000만 달러에서 2032년에는 23억 1,000만 달러로 성장하며, 예측 기간 중(2025-2032년) CAGR 5.7%로 성장할 전망입니다.

세계의 브루가다 증후군 시장은 심장의 전기적 시스템을 교란시키는 이 희귀 유전질환의 유병률이 증가함에 따라 심혈관 건강에 큰 변화가 일어나고 있습니다. 유전자 검사 기술의 발전과 맞춤형 의료에 대한 관심이 높아짐에 따라 인지도가 높아지면서 더 나은 진단 및 치료 전략이 개발되고 있습니다. 이러한 긍정적인 변화에도 불구하고 조기 발견과 질환의 복잡성 이해에 대한 과제는 여전히 남아 있으며, 이는 현재 진행 중인 연구 구상을 촉진하고 있습니다. 경쟁 환경의 특징은 제약회사, 진단 실험실, 의료기기 제조업체 간의 협력으로, 이들 모두 브루가다 증후군 관리에서 충족되지 않은 요구를 충족시키기 위해 노력하고 있다는 점입니다. 전반적으로 이해관계자들이 협력하여 환자의 결과를 개선하고 치료 옵션을 넓히기 위해 노력하는 이 시장은 유망한 시장입니다.

목차

서론

  • 조사의 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차 데이터와 1차 데이터 방법
  • 시장 규모 예측
  • 시장의 전제조건과 제한

개요

  • 세계 시장 전망
  • 공급과 수요의 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장 에코시스템
  • 시장의 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석
  • 규제 상황
  • 사례 연구
  • 기술의 진보

브루가다 증후군 시장 규모 : 진단별

  • 시장 개요
  • 심전도
  • 전기생리학(Ep) 검사
  • 유전자 검사

브루가다 증후군 시장 규모 : 약물별

  • 시장 개요
  • 항부정맥약
  • 향정신약
  • 마취제/진통제
  • 기타

브루가다 증후군 시장 규모 : 치료별

  • 시장 개요
  • 이식형 제세동기
  • 약물 요법

브루가다 증후군 시장 규모 : 최종사용자별

  • 시장 개요
  • 병원
  • 클리닉
  • 진단 센터
  • 기타

브루가다 증후군 시장 규모

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카 지역
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채택한 전략
  • 시장의 최근 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업의 기업 개요
    • 회사 개요
    • 제품 포트폴리오 분석
    • 부문별 점유율 분석
    • 매출의 전년대비 비교(2022-2024)

주요 기업 개요

  • Boston Scientific Corporation(USA)
  • LivaNova plc(UK)
  • Medtronic(USA)
  • Abbott(USA)
  • Edwards Lifesciences Corporation(USA)
  • Novartis AG(Switzerland)
  • Sun Pharmaceutical Industries Ltd.(India)
  • MRI Interventions(USA)
  • HeartSine Technologies LLC(USA)
  • GeneDx(USA)
  • PGxHealth LLC(USA)
  • GE Healthcare(UK)
  • Pfizer, Inc(USA)
  • GlaxoSmithKline(UK)
  • Eli Lilly Company(USA)
  • Taj Pharmaceuticals Ltd(India)
  • Biotronik SE & Co. KG(Germany)
  • MicroPort Scientific Corporation(China)
  • St. Jude Medical, Inc.(USA)
  • Conmed Corporation(USA)

결론과 권장사항

KSA 25.02.24

Global Brugada Syndrome Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.48 billion in 2024 to USD 2.31 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global Brugada syndrome market is experiencing significant transformation within cardiovascular health due to the rising prevalence of this rare genetic disorder that disrupts the heart's electrical system. Enhanced awareness is driving better diagnosis and treatment strategies, bolstered by advancements in genetic testing technologies and an increasing emphasis on personalized medicine. Despite these positive shifts, challenges in early detection and comprehension of the syndrome's intricacies persist, prompting ongoing research initiatives. The competitive landscape is marked by collaboration among pharmaceutical companies, diagnostic labs, and medical device manufacturers, all striving to meet the unmet needs in managing Brugada syndrome. Overall, the market shows promise as stakeholders work together to improve patient outcomes and expand treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Brugada Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Brugada Syndrome Market Segmental Analysis

Global Brugada Syndrome Market is segmented by Diagnosis, Drugs, Treatment, End user and region. Based on Diagnosis, the market is segmented into Electrocardiogram, Electrophysiology (Ep) Test and Genetic Testing. Based on Drugs, the market is segmented into Antiarrhythmic drugs, Psychotropic drugs, Anesthetics/analgesics and Others. Based on Treatment, the market is segmented into Implantable Cardioverter-Defibrillator and Drug Therapy. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Brugada Syndrome Market

The Brugada Syndrome market is significantly driven by the growing awareness and comprehension of the condition among both healthcare providers and the general public. As knowledge about Brugada syndrome expands, it leads to earlier diagnosis and timely intervention, which ultimately enhances patient outcomes. This collective understanding encourages medical professionals to recognize the symptoms more effectively and promotes education initiatives aimed at informing the public. Consequently, such advancements not only improve the rate of detection but also empower patients with knowledge about their condition, fostering a more proactive approach to management and treatment in the expanding Brugada syndrome market.

Restraints in the Global Brugada Syndrome Market

A significant constraint in the global Brugada Syndrome market is the insufficient understanding of its underlying mechanisms. This complex genetic disorder presents challenges in achieving accurate diagnoses and developing targeted treatment options. The lack of comprehensive knowledge hampers advancements in research and impedes effective strategies for managing the condition. As a result, healthcare professionals may struggle to identify the syndrome promptly or to provide the most appropriate therapies, ultimately limiting market growth and innovation in this area. Overcoming this limitation is crucial for improving patient outcomes and advancing the overall understanding of Brugada Syndrome.

Market Trends of the Global Brugada Syndrome Market

The Global Brugada Syndrome market is witnessing a notable trend towards the rising emphasis on genetic testing, fueled by an enhanced understanding of the genetic underpinnings of the condition. Advances in genomic technologies have paved the way for more precise and accessible genetic analyses that identify mutations linked to Brugada syndrome. Concurrently, the integration of artificial intelligence (AI) in electrocardiogram (ECG) analysis is transforming diagnosis, enabling automated detection of subtle cardiac abnormalities that may otherwise go unnoticed. This confluence of genetic insights and technological innovations is poised to improve patient outcomes and drive continued growth in the Brugada Syndrome market.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Regulatory Landscape
  • Case Studies
  • Technological Advancement

Global Brugada Syndrome Market Size by Diagnosis & CAGR (2025-2032)

  • Market Overview
  • Electrocardiogram
  • Electrophysiology (Ep) Test
  • Genetic Testing

Global Brugada Syndrome Market Size by Drugs & CAGR (2025-2032)

  • Market Overview
  • Antiarrhythmic drugs
  • Psychotropic drugs
  • Anesthetics/Analgesics
  • Others

Global Brugada Syndrome Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Implantable Cardioverter-Defibrillator
  • Drug Therapy

Global Brugada Syndrome Market Size by End user & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Others

Global Brugada Syndrome Market Size & CAGR (2025-2032)

  • North America (Diagnosis, Drugs, Treatment, End user)
    • US
    • Canada
  • Europe (Diagnosis, Drugs, Treatment, End user)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Diagnosis, Drugs, Treatment, End user)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Diagnosis, Drugs, Treatment, End user)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Diagnosis, Drugs, Treatment, End user)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Boston Scientific Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LivaNova plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medtronic (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Edwards Lifesciences Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • MRI Interventions (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • HeartSine Technologies LLC (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GeneDx (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PGxHealth LLC (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GE Healthcare (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer, Inc (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Taj Pharmaceuticals Ltd (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biotronik SE & Co. KG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • MicroPort Scientific Corporation (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • St. Jude Medical, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Conmed Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제